416 related articles for article (PubMed ID: 28225768)
21. Modest but sustained increase of serum high density lipoprotein cholesterol levels in patients with inflammatory arthritides treated with infliximab.
Spanakis E; Sidiropoulos P; Papadakis J; Ganotakis E; Katsikas G; Karvounaris S; Bizaki A; Kritikos H; Boumpas DT
J Rheumatol; 2006 Dec; 33(12):2440-6. PubMed ID: 17014005
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and tolerability of anti-tumour necrosis factor therapy in psoriatic arthritis patients: results from the South Swedish Arthritis Treatment Group register.
Kristensen LE; Gülfe A; Saxne T; Geborek P
Ann Rheum Dis; 2008 Mar; 67(3):364-9. PubMed ID: 17644547
[TBL] [Abstract][Full Text] [Related]
23. Methylenetetrahydrofolate reductase polymorphisms and methotrexate: no association with response to therapy nor with drug-related adverse events in an Italian population of rheumatic patients.
Taraborelli M; Andreoli L; Archetti S; Ferrari M; Cattaneo R; Tincani A
Clin Exp Rheumatol; 2009; 27(3):499-502. PubMed ID: 19604445
[TBL] [Abstract][Full Text] [Related]
24. Erythrocyte sedimentation rate, C-reactive protein level, and serum amyloid a protein for patient selection and monitoring of anti-tumor necrosis factor treatment in ankylosing spondylitis.
de Vries MK; van Eijk IC; van der Horst-Bruinsma IE; Peters MJ; Nurmohamed MT; Dijkmans BA; Hazenberg BP; Wolbink GJ
Arthritis Rheum; 2009 Nov; 61(11):1484-90. PubMed ID: 19877087
[TBL] [Abstract][Full Text] [Related]
25. E-selectin, interleukin 18, serum amyloid a, and matrix metalloproteinase 9 are associated with clinical response to golimumab plus methotrexate in patients with active rheumatoid arthritis despite methotrexate therapy.
Visvanathan S; Wagner C; Rojas J; Kay J; Dasgupta B; Matteson EL; Mack M; Baker DG; Rahman MU
J Rheumatol; 2009 Jul; 36(7):1371-9. PubMed ID: 19487269
[TBL] [Abstract][Full Text] [Related]
26. Effects of anti-TNF therapy on glucose metabolism in patients with ankylosing spondylitis, psoriatic arthritis or juvenile idiopathic arthritis.
da Silva BS; Bonfá E; de Moraes JC; Saad CG; Ribeiro AC; Gonçalves CR; de Carvalho JF
Biologicals; 2010 Sep; 38(5):567-9. PubMed ID: 20638299
[TBL] [Abstract][Full Text] [Related]
27. Differing local and systemic inflammatory burden in polyarticular psoriatic arthritis and rheumatoid arthritis patients on anti-TNF treatment in clinical remission.
Ramírez J; Inciarte-Mundo J; Cuervo A; Ruiz-Esquide V; Hernández MV; Sanmartí R; Cañete JD
Clin Exp Rheumatol; 2017; 35(1):74-79. PubMed ID: 27749227
[TBL] [Abstract][Full Text] [Related]
28. The role of methotrexate co-medication in TNF-inhibitor treatment in patients with psoriatic arthritis: results from 440 patients included in the NOR-DMARD study.
Fagerli KM; Lie E; van der Heijde D; Heiberg MS; Lexberg AS; Rødevand E; Kalstad S; Mikkelsen K; Kvien TK
Ann Rheum Dis; 2014 Jan; 73(1):132-7. PubMed ID: 23291385
[TBL] [Abstract][Full Text] [Related]
29. Long pentraxin 3: a marker of inflammation in untreated psoriatic patients.
Bevelacqua V; Libra M; Mazzarino MC; Gangemi P; Nicotra G; Curatolo S; Massimino D; Plumari A; Merito P; Valente G; Stivala F; La Greca S; Malaponte G
Int J Mol Med; 2006 Sep; 18(3):415-23. PubMed ID: 16865225
[TBL] [Abstract][Full Text] [Related]
30. Increased matrix metalloproteinase-3 serum levels in rheumatic diseases: relationship with synovitis and steroid treatment.
Ribbens C; Martin y Porras M; Franchimont N; Kaiser MJ; Jaspar JM; Damas P; Houssiau FA; Malaise MG
Ann Rheum Dis; 2002 Feb; 61(2):161-6. PubMed ID: 11796404
[TBL] [Abstract][Full Text] [Related]
31. Clinical remission following treatment with tumour necrosis factor-alpha antagonists is not accompanied by changes in asymmetric dimethylarginine in patients with rheumatoid arthritis.
Sandoo A; Dimitroulas T; Toms TE; Hodson J; Veldhuijzen van Zanten JJ; Smith JP; Kitas GD
Clin Biochem; 2012 Nov; 45(16-17):1399-403. PubMed ID: 22820438
[TBL] [Abstract][Full Text] [Related]
32. Golimumab: a new anti-TNF-alpha agent for rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.
Voulgari PV
Expert Rev Clin Immunol; 2010 Sep; 6(5):721-33. PubMed ID: 20828280
[TBL] [Abstract][Full Text] [Related]
33. Serum survivin predicts responses to treatment in active rheumatoid arthritis: a post hoc analysis from the SWEFOT trial.
Levitsky A; Erlandsson MC; van Vollenhoven RF; Bokarewa MI
BMC Med; 2015 Sep; 13():247. PubMed ID: 26420684
[TBL] [Abstract][Full Text] [Related]
34. Real-world anti-tumor necrosis factor treatment in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: cost-effectiveness based on number needed to treat to improve health assessment questionnaire.
Barra L; Pope JE; Payne M
J Rheumatol; 2009 Jul; 36(7):1421-8. PubMed ID: 19487267
[TBL] [Abstract][Full Text] [Related]
35. Raised circulating tenascin-C in rheumatoid arthritis.
Page TH; Charles PJ; Piccinini AM; Nicolaidou V; Taylor PC; Midwood KS
Arthritis Res Ther; 2012 Nov; 14(6):R260. PubMed ID: 23193984
[TBL] [Abstract][Full Text] [Related]
36.
Iwaszko M; Wielińska J; Świerkot J; Kolossa K; Sokolik R; Bugaj B; Chaszczewska-Markowska M; Jeka S; Bogunia-Kubik K
Front Immunol; 2021; 12():631603. PubMed ID: 34177886
[TBL] [Abstract][Full Text] [Related]
37. Biologics and cardiovascular events in inflammatory arthritis: a prospective national cohort study.
Lee JL; Sinnathurai P; Buchbinder R; Hill C; Lassere M; March L
Arthritis Res Ther; 2018 Aug; 20(1):171. PubMed ID: 30086795
[TBL] [Abstract][Full Text] [Related]
38. Impact of treatment with TNF antagonists on total cholesterol in patients with ankylosing spondylitis and psoriatic arthritis.
Maneiro JR; Souto A; Gomez-Reino JJ
Clin Rheumatol; 2017 May; 36(5):1167-1172. PubMed ID: 28108800
[TBL] [Abstract][Full Text] [Related]
39. Circulating and Synovial Pentraxin-3 (PTX3) Expression Levels Correlate With Rheumatoid Arthritis Severity and Tissue Infiltration Independently of Conventional Treatments Response.
Boutet MA; Nerviani A; Lliso-Ribera G; Leone R; Sironi M; Hands R; Rivellese F; Del Prete A; Goldmann K; Lewis MJ; Mantovani A; Bottazzi B; Pitzalis C
Front Immunol; 2021; 12():686795. PubMed ID: 34248970
[TBL] [Abstract][Full Text] [Related]
40. Golimumab: Review of the efficacy and tolerability of a recently approved tumor necrosis factor-α inhibitor.
Boyce EG; Halilovic J; Stan-Ugbene O
Clin Ther; 2010 Sep; 32(10):1681-703. PubMed ID: 21194591
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]